This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval
by Kinjel Shah
AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.
Puma (PBYI) Stock Down Despite Q4 Earnings & Sales Beat
by Zacks Equity Research
Puma Biotech (PBYI) incurs narrower loss in Q4 and tops sales estimates. Sales of Nerlynx decline year over year. Stock drops 10%.
Intellia (NTLA) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Intellia (NTLA) is likely to provide an update on the IND application for its lead candidate NTLA-2001, currently being developed to address transthyretin amyloidosis.
Glaxo Underperforms Industry in a Year: What's in Store?
by Zacks Equity Research
Shares of Glaxo (GSK) lag the industry in a year as generic erosion of some drugs mainly its top-selling drug, Advair offsets strong sales of new drugs.
AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates
by Zacks Equity Research
AstraZeneca (AZN) misses estimates for earnings and sales. However, new drugs, mainly cancer medicines, continue to drive product sales higher.
Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review
by Zacks Equity Research
Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.
Incyte (INCY) Q4 Earnings Top Estimates on Solid Jakafi Sales
by Zacks Equity Research
Incyte (INCY) beats on earnings & sales in the fourth quarter on strong Jakafi growth.
Pfizer's Xtandi Improves OS Rate in Prostate Cancer Study
by Zacks Equity Research
Pfizer's (PFE) Xtandi demonstrates a significant improvement in overall survival in the late-stage PROSPER study that evaluated the drug in men with non-metastatic castration-resistant prostate cancer.
Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Gilead's (GILD) BLA for its second CAR T cell therapy, KTE-X19.
Lilly Reports Disappointing Data on Alzheimer's Candidate
by Zacks Equity Research
Eli Lilly's (LLY) Alzheimer's disease drug, solanezumab, fails to meet primary endpoint in a phase II/III investigator-led study.
Incyte's (INCY) Capmatinib NDA Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts Incyte's (INCY) NDA for capmatinib and grants Priority Review.
Roche Reports Disappointing Data on Alzheimer's Disease Drug
by Zacks Equity Research
Roche's (RHHBY) Alzheimer's disease drug fails to meet primary endpoint in a phase II/III study.
Regeneron Reports Positive Eylea Data From Late-Stage Study
by Zacks Equity Research
Regeneron (REGN) announces positive two-year results from the phase III PANORAMA study on lead ophthalmology drug, Eylea.
Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Ligand (LGND) reports higher-than-expected fourth-quarter 2019 earnings and revenues.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports fourth-quarter 2019 results.
Alnylam's (ALNY) Q4 Earnings Miss Estimates, Sales Beat
by Zacks Equity Research
Alnylam (ALNY) posts a wider-than-expected loss, while revenues beat estimates marginally in the fourth quarter of 2019.
Regeneron's (REGN) Q4 Earnings & Sales Surpass Estimates
by Zacks Equity Research
Regeneron (REGN) beats on Q4 earnings and sales on solid performance of ophthalmology drug, Eylea, and asthma drug, Dupixent.
Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal
by Zacks Equity Research
Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.
Is a Disappointment in Store for Glaxo's (GSK) Q4 Earnings?
by Zacks Equity Research
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales in the fourth quarter.
The Zacks Analyst Blog Highlights: Microsoft, Facebook, Novartis, Tesla and Raytheon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Facebook, Novartis, Tesla and Raytheon
Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative
by Kinjel Shah
Lilly (LLY), Pfizer (PFE) and Novartis (NVS) announce Q4 results.
Top Stock Analyst Reports for Microsoft, Facebook & Novartis
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Facebook (FB) and Novartis (NVS).
Roche (RHHBY) 2019 Sales Solid on Robust Show by New Drugs
by Zacks Equity Research
Roche's (RHHBY) performance in 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.
Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal
by Zacks Equity Research
Incyte (INCY) posts positive top-line results from late-stage TRuE-AD2 study on ruxolitinib cream to treat adolescent and adult patients with atopic dermatitis. The study achieves its main goal.
Novartis (NVS) Earnings and Revenues Miss Estimates in Q4
by Zacks Equity Research
Novartis (NVS) reports disappointing results for the fourth quarter but provides an encouraging outlook for 2020.